CAPR$24.04
$24.0
Chart
Performance
Key Stats
AI CAPR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldCapricor Therapeutics (CAPR) shows potential in its clinical development for Duchenne Muscular Dystrophy, but faces significant financial and market volatility. The current technical indicators suggest a period of consolidation or potential downside risk. Investors should monitor clinical trial progress and market sentiment closely.
Thematic
Capricor Therapeutics operates in the biotechnology sector, specifically focusing on cell and exosome-based therapeutics for rare diseases like Duchenne Muscular Dystrophy (DMD). The thematic potential is tied to advancements in gene therapy and regenerative medicine.
Fundamental
Capricor Therapeutics exhibits high cash burn and negative earnings, typical of a clinical-stage biotech. Its financial health is dependent on future capital raises or successful drug commercialization.
Technical
CAPR's recent performance has been highly volatile. While it experienced a strong 1-year gain, the past 6 months and YTD show significant declines. Technical indicators suggest mixed signals, with some short-term bullishness but longer-term trends indicating weakness.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 70 |
| Rare Disease Market | 75 |
| Clinical Trial Success Risk | 40 |
| Regulatory Landscape (FDA) | 65 |
| Competitive Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 40 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume Confirmation | 60 |
| Support & Resistance | 55 |
| Performance Trends | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Strong Short-Term Momentum
The 5-day performance is positive at 3.99%, suggesting recent upward price movement.
Above Average Volume
The current volume (1,060,949) is significantly lower than the 30-day average volume (3,947,310), which could indicate less speculative interest, or if the price is moving up, it could suggest conviction from a smaller, more engaged group of buyers. If the price is falling, it might indicate a lack of strong selling pressure relative to the average.
Bearish Points (11)
Significant Medium-Term Decline
The stock has experienced substantial negative performance over the last 1, 6, and YTD periods (-39.19%, -52.49%, -54.68% respectively), indicating significant downward price pressure and investor caution.
Low Dividend Yield
The dividend yield is 0.0%, meaning the company does not currently pay dividends to shareholders, which might be less attractive to income-focused investors.
Calendar
June 2019
5
Next Dividend Date
August 2025
6
Next Earnings Date
H: $-0.43
A: $-0.48
L: $-0.54
H: 3.00M
A: 778.00K
0Profile
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Seasonals
Price Target
20.60 USD
The 39 analysts offering 1 year price forecasts for CAPR have a max estimate of 29.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading competitor in Duchenne Muscular Dystrophy (DMD) therapies, with multiple approved treatments and gene therapy candidates directly competing with CAPR's focus.
Weight: 90
Developing a late-stage gene therapy for DMD, representing a significant direct competitive threat in CAPR's primary therapeutic area.
Weight: 88
Developing gene therapies for DMD, making it a direct peer and competitor in a highly specialized and competitive field.
Weight: 85
Has approved drugs and pipeline candidates for DMD (e.g., Emflaza, Translarna in some regions), positioning it as a key player in the DMD market.